Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?
Tally Is Behind Recent Years
Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.
You may also be interested in...
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.
Industry investors foresee continued hardship for public companies still without compelling clinical data for their assets, plus the growing influence of the US Inflation Reduction Act on biopharma strategy.
In this week's podcast edition of Five Must-Know Things: Merck and Moderna’s cancer vaccine deal; six pivotal trial readouts to look out for in Q4; Pfizer leads big pharma M&A so far this year; making the metaverse work in pharma; and a first approval for a Chinese mRNA vaccine.